Literature DB >> 19956372

Expressions of matrix metalloproteinase-7 and -9 and their prognostic significances in rectal cancer.

Young Rak Cho1, Hyuk-Chan Kwon, Sung-Hwan Suh, Jong Hoon Lee, Sung-Hyun Kim, Hong-Jo Choi, Hyung-Sik Lee, Mee Sook Roh, Tae-Ho Hwang, Jae-Seok Kim, Hyo-Jin Kim.   

Abstract

PURPOSE: The matrix metalloproteinases (MMPs) are a family of proteolytic enzymes. MMPs are known to be involved in tumor invasion, and several have been implicated in tumor prognosis. The aim of this study was to evaluate the prognostic significances of the expressions of MMP-7 and -9 in rectal cancer.
MATERIALS AND METHODS: The tumor tissues of 87 patients with stage II or III rectal carcinoma that underwent potentially curative resection followed by postoperative adjuvant chemoradiation and 5-fluorouracil based chemotherapy, were investigated immunohistochemically using monoclonal antibodies against MMP-7 and MMP-9. Clinical information, including tumor grades, carcinoembryonic antigen (CEA) levels, and disease-free survival and overall survival were evaluated with respect to the expressions of MMP-7 and -9.
RESULTS: Median follow-up duration was 53.2 months, and median patient age was 55±11 years (range 32~75). MMP-7 expression in tumor tissue was found to be significantly correlated with the presence of nodal metastasis (p=0.029), whilst MMP-9 expression correlated with depth of tumor invasion (p=0.019). No relationships were found between the expressions of MMP-7 or -9 and age, sex, tumor size, tumor grade, or CEA level. Univariate analysis showed that MMP-7 expression was associated with poor 5-year overall survival (12.8 months vs. 65.3 months, p=0.0405). Multivariate analysis confirmed that MMP-7 was independently associated with an adverse outcome (Relative risk: 1.415, p=0.027). However, MMP-9 expression was not found to be related to clinical outcome.
CONCLUSION: MMP-7 expression in tumor tissue is associated with lymph node metastasis and a poor 5-year overall survival in rectal cancer patients.

Entities:  

Keywords:  Immunohistochemistry; Matrix metalloproteinases; Prognosis; Rectal carcinoma

Year:  2005        PMID: 19956372      PMCID: PMC2785939          DOI: 10.4143/crt.2005.37.6.354

Source DB:  PubMed          Journal:  Cancer Res Treat        ISSN: 1598-2998            Impact factor:   4.679


  21 in total

1.  Host expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in normal colon tissue affects metastatic potential of colorectal cancer.

Authors:  H Masuda; H Aoki
Journal:  Dis Colon Rectum       Date:  1999-03       Impact factor: 4.585

2.  Activity and cellular origin of gelatinases in patients with colon and rectal carcinoma differential activity of matrix metalloproteinase-9.

Authors:  E Roeb; C G Dietrich; R Winograd; M Arndt; B Breuer; J Fass; V Schumpelick; S Matern
Journal:  Cancer       Date:  2001-11-15       Impact factor: 6.860

3.  Clinicopathologic and prognostic significance of matrilysin expression at the invasive front in human colorectal cancers.

Authors:  Y Adachi; H Yamamoto; F Itoh; Y Arimura; M Nishi; T Endo; K Imai
Journal:  Int J Cancer       Date:  2001-09-20       Impact factor: 7.396

4.  Purification and characterization of extracellular matrix-degrading metalloproteinase, matrin (pump-1), secreted from human rectal carcinoma cell line.

Authors:  K Miyazaki; Y Hattori; F Umenishi; H Yasumitsu; M Umeda
Journal:  Cancer Res       Date:  1990-12-15       Impact factor: 12.701

5.  Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers.

Authors:  Y Adachi; H Yamamoto; F Itoh; Y Hinoda; Y Okada; K Imai
Journal:  Gut       Date:  1999-08       Impact factor: 23.059

6.  Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9.

Authors:  Z S Zeng; Y Huang; A M Cohen; J G Guillem
Journal:  J Clin Oncol       Date:  1996-12       Impact factor: 44.544

7.  Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study.

Authors:  Megan M Garrity; Lawrence J Burgart; Michelle R Mahoney; Harold E Windschitl; Muhammad Salim; Martin Wiesenfeld; James E Krook; John C Michalak; Richard M Goldberg; Michael J O'Connell; Alfred F Furth; Daniel J Sargent; Linda M Murphy; Eunice Hill; Darren L Riehle; Cecelia H Meyers; Thomas E Witzig
Journal:  J Clin Oncol       Date:  2004-05-01       Impact factor: 44.544

Review 8.  Role of matrix metalloproteinases (MMPs) in colorectal cancer.

Authors:  Stanley Zucker; Jeffrey Vacirca
Journal:  Cancer Metastasis Rev       Date:  2004 Jan-Jun       Impact factor: 9.264

9.  Effective surgical adjuvant therapy for high-risk rectal carcinoma.

Authors:  J E Krook; C G Moertel; L L Gunderson; H S Wieand; R T Collins; R W Beart; T P Kubista; M A Poon; W C Meyers; J A Mailliard
Journal:  N Engl J Med       Date:  1991-03-14       Impact factor: 91.245

10.  Spectrum of matrix metalloproteinase expression in primary and metastatic colon cancer: relationship to the tissue inhibitors of metalloproteinases and membrane type-1-matrix metalloproteinase.

Authors:  H M Collins; T M Morris; S A Watson
Journal:  Br J Cancer       Date:  2001-06-15       Impact factor: 7.640

View more
  2 in total

1.  Matrix metalloproteinase 9 expression and prognosis in colorectal cancer: a meta-analysis.

Authors:  Chun-Yu Li; Peng Yuan; Shu-Sen Lin; Cheng-Fei Song; Wei-Yu Guan; Lu Yuan; Rong-Bin Lai; Ying Gao; Yan Wang
Journal:  Tumour Biol       Date:  2012-12-27

Review 2.  Effects of radiation on the metastatic process.

Authors:  Nora Sundahl; Fréderic Duprez; Piet Ost; Wilfried De Neve; Marc Mareel
Journal:  Mol Med       Date:  2018-04-24       Impact factor: 6.354

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.